Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Untangling the clinical and economic burden of hospitalization for cardiac amyloidosis in the United States. Clinicoecon Outcomes Res 2019;11:431-439

Date

08/15/2019

Pubmed ID

31410040

Pubmed Central ID

PMC6643051

DOI

10.2147/CEOR.S207127

Abstract

Purpose: Cardiac dysfunction is common in amyloid light-chain (AL) amyloidosis, a rare disease caused by extracellular deposition of misfolded immunoglobulin light chains. This study aimed to examine economic/clinical disease burden in hospitalized cardiac amyloidosis patients.

Patients and methods: Cardiac amyloidosis patients ≥18 years old hospitalized between 2014 and 2016 were identified in claims if they had ≥1 inpatient claim consistent with amyloidosis and evidence of cardiac dysfunction. Descriptive statistics were reported.

Results: 3239 cardiac amyloidosis patients [1795 (55.4%) with concurrent renal disease] were identified. Mean (SD) length of stay was 8.3 (11.1) days. 25.2% were admitted to the intensive care unit. Mean overall hospitalization costs were USD$20,584. In-hospital mortality was 9.0% overall. 16.8% were readmitted within 30 days, with 11.2% dying in-hospital and a mean readmission cost of USD$18,536.

Conclusion: Hospitalization for cardiac amyloidosis is costly, with high rates of readmission and mortality. Opportunities exist to improve care.

Author List

Quock TP, Yan T, Tieu R, D'Souza A, Broder MS

Author

Anita D'Souza MD Associate Professor in the Medicine department at Medical College of Wisconsin




jenkins-FCD Prod-482 91ad8a360b6da540234915ea01ff80e38bfdb40a